Defective repair of oxidative dna damage in triple-negative breast cancer confers sensitivity to inhibition of poly(ADP-ribose) polymerase.

Subtypes of breast cancer that represent the two major types of epithelial cells in the breast (luminal and basal) carry distinct histopathologic profiles. Breast cancers of the basal-like subtype, which include the majority of hereditary breast cancers due to mutations in the breast cancer susceptibility gene 1 (BRCA1), frequently assume triple-negative status, i.e., they lack expression of estrogen receptor-alpha and progesterone receptor, and lack overexpression or amplification of the HER2/NEU oncogene. Defects in DNA damage response pathways result in genome instability and lead to carcinogenesis, but may also be exploited for therapeutic purposes. We analyzed repair of oxidative DNA damage by the base-excision repair (BER) pathway, which when aberrant leads to genomic instability and breast carcinogenesis, in cell lines that represent the different subtypes of breast cancer and in the presence of BRCA1 deficiency. We found that basal-like and BRCA1-mutated breast cancer cells were defective in BER of oxidative DNA damage, and that this defect conferred sensitivity to inhibition of poly(ADP-ribose) polymerase, a DNA repair enzyme. The defect may be attributed, at least in part, to a novel role for BRCA1 in the BER pathway. Overall, these data offer preventive, prognostic, and therapeutic usefulness.

[1]  Alan Ashworth,et al.  A synthetic lethal therapeutic approach: poly(ADP) ribose polymerase inhibitors for the treatment of cancers deficient in DNA double-strand break repair. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  Ian O Ellis,et al.  Basal-like breast cancer: a critical review. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  K. Hess,et al.  Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  J Wade Harper,et al.  The DNA damage response: ten years after. , 2007, Molecular cell.

[5]  Heinrich Leonhardt,et al.  Feedback-regulated poly(ADP-ribosyl)ation by PARP-1 is required for rapid response to DNA damage in living cells , 2007, Nucleic acids research.

[6]  S. Narod,et al.  Triple-Negative Breast Cancer: Clinical Features and Patterns of Recurrence , 2007, Clinical Cancer Research.

[7]  Marc Tischkowitz,et al.  Use of immunohistochemical markers can refine prognosis in triple negative breast cancer , 2007, BMC Cancer.

[8]  R. Cress,et al.  Descriptive analysis of estrogen receptor (ER)‐negative, progesterone receptor (PR)‐negative, and HER2‐negative invasive breast cancer, the so‐called triple‐negative phenotype , 2007, Cancer.

[9]  C. Perou,et al.  The Triple Negative Paradox: Primary Tumor Chemosensitivity of Breast Cancer Subtypes , 2007, Clinical Cancer Research.

[10]  M. Evans,et al.  Lymphoblasts of women with BRCA1 mutations are deficient in cellular repair of 8,5'-Cyclopurine-2'-deoxynucleosides and 8-hydroxy-2'-deoxyguanosine. , 2007, Biochemistry.

[11]  J. Weidhaas,et al.  Locoregional relapse and distant metastasis in conservatively managed triple negative early-stage breast cancer. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  Wen-Lin Kuo,et al.  A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes. , 2006, Cancer cell.

[13]  J. Reis-Filho,et al.  Basal-like breast cancer and the BRCA1 phenotype , 2006, Oncogene.

[14]  A. Nobel,et al.  The molecular portraits of breast tumors are conserved across microarray platforms , 2006, BMC Genomics.

[15]  A. Chatterjee,et al.  The effect of p53‐RNAi and p53 knockout on human 8‐oxoguanine DNA glycosylase (hOgg1) activity , 2006, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[16]  S. Powell,et al.  The Role of the BRCA1 Tumor Suppressor in DNA Double-Strand Break Repair , 2005, Molecular Cancer Research.

[17]  Julian Peto,et al.  Prediction of BRCA1 Status in Patients with Breast Cancer Using Estrogen Receptor and Basal Phenotype , 2005, Clinical Cancer Research.

[18]  P. Storz Reactive oxygen species in tumor progression. , 2005, Frontiers in bioscience : a journal and virtual library.

[19]  Alan Ashworth,et al.  Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy , 2005, Nature.

[20]  Thomas Helleday,et al.  Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase , 2005, Nature.

[21]  L. Chodosh,et al.  Brca1-Deficient Murine Mammary Epithelial Cells have Increased Sensitivity to CDDP and MMS , 2004, Cell cycle.

[22]  G. Achanta,et al.  Role of p53 in Sensing Oxidative DNA Damage in Response to Reactive Oxygen Species-Generating Agents , 2004, Cancer Research.

[23]  A. Gown,et al.  Immunohistochemical and Clinical Characterization of the Basal-Like Subtype of Invasive Breast Carcinoma , 2004, Clinical Cancer Research.

[24]  William D. Foulkes,et al.  Re: Germline BRCA1 Mutations and a Basal Epithelial Phenotype in Breast Cancer , 2004 .

[25]  L. Bégin,et al.  Germline BRCA1 mutations and a basal epithelial phenotype in breast cancer. , 2004, Journal of the National Cancer Institute.

[26]  J. Klaunig,et al.  The role of oxidative stress in carcinogenesis. , 2004, Annual review of pharmacology and toxicology.

[27]  Zhihui Feng,et al.  Chk2 Phosphorylation of BRCA1 Regulates DNA Double-Strand Break Repair , 2004, Molecular and Cellular Biology.

[28]  A. Hartman,et al.  BRCA1 and p53: compensatory roles in DNA repair , 2003, Journal of Molecular Medicine.

[29]  R. Tibshirani,et al.  Repeated observation of breast tumor subtypes in independent gene expression data sets , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[30]  J. Ford,et al.  BRCA1 induces DNA damage recognition factors and enhances nucleotide excision repair , 2002, Nature Genetics.

[31]  M. J. van de Vijver,et al.  The pathology of familial breast cancer: predictive value of immunohistochemical markers estrogen receptor, progesterone receptor, HER-2, and p53 in patients with mutations in BRCA1 and BRCA2. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[32]  S. Amundson,et al.  Implication of p53 in base excision DNA repair: in vivo evidence , 2002, Oncogene.

[33]  Thomas D. Schmittgen,et al.  Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. , 2001, Methods.

[34]  R. Tibshirani,et al.  Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[35]  A. Jackson,et al.  The contribution of endogenous sources of DNA damage to the multiple mutations in cancer. , 2001, Mutation research.

[36]  Samuel H. Wilson,et al.  A role for p53 in base excision repair , 2001, The EMBO journal.

[37]  Christian A. Rees,et al.  Molecular portraits of human breast tumours , 2000, Nature.

[38]  E. Berns,et al.  Is TP53 dysfunction required for BRCA1-associated carcinogenesis? , 1999, Molecular and Cellular Endocrinology.

[39]  V. Rotter,et al.  Direct involvement of p53 in the base excision repair pathway of the DNA repair machinery , 1999, FEBS letters.

[40]  A. Moor,et al.  Photodynamic treatment of adenoviral vectors with visible light: an easy and convenient method for viral inactivation , 1999, Gene Therapy.

[41]  M. Westerfield,et al.  Characterization of paired tumor and non‐tumor cell lines established from patients with breast cancer , 1998, International journal of cancer.

[42]  J. Peto,et al.  p53 mutation with frequent novel codons but not a mutator phenotype in BRCA1- and BRCA2-associated breast tumours , 1998, Oncogene.

[43]  J. Minna,et al.  Characterization of a breast cancer cell line derived from a germ-line BRCA1 mutation carrier. , 1998, Cancer research.

[44]  J. T. Reardon,et al.  In vitro repair of oxidative DNA damage by human nucleotide excision repair system: possible explanation for neurodegeneration in xeroderma pigmentosum patients. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[45]  A. Collins,et al.  Oxidative damage to DNA: do we have a reliable biomarker? , 1996, Environmental health perspectives.

[46]  N. Polissar,et al.  Progression of human breast cancers to the metastatic state is linked to hydroxyl radical-induced DNA damage. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[47]  M. Seller,et al.  Unusual case of Smith-Lemli-Opitz syndrome "type II". , 1995, American journal of medical genetics.

[48]  D. Easton,et al.  Risks of cancer in BRCA1-mutation carriers , 1994, The Lancet.

[49]  D. Bishop,et al.  Breast and Ovarian Cancer Incidence in BRCA I -Mutation Carriers , 2007 .

[50]  A. Hollestelle,et al.  BRCA1 mutation analysis of 41 human breast cancer cell lines reveals three new deleterious mutants. , 2006, Cancer research.

[51]  M. Dusinska,et al.  Comet assay in human biomonitoring studies: Reliability, validation, and applications , 1997, Environmental and molecular mutagenesis.

[52]  D. Easton,et al.  Breast and ovarian cancer incidence in BRCA1-mutation carriers. Breast Cancer Linkage Consortium. , 1995, American journal of human genetics.